Chinese Japanese Germany Korea

Moxifloxacin hydrochloride

Indications and Usage Mechanisms of Action Pharmacokinetics Adverse Effects Warnings and Precautions Adverse reactions Precautions
Moxifloxacin hydrochloride
Moxifloxacin hydrochloride structure
Chemical Name:
Moxifloxacin hydrochloride
AVALOX;Actura;ACTIRA;Avelox;MoxifL;PROFLOX;BAY-12-8039;BAY12-8039 HCl;AVELOX; AVALOX;oxacin hydrochL
Molecular Formula:
Formula Weight:
MOL File:

Moxifloxacin hydrochloride Properties

Melting point:
Slightly yellow to yellow crystalline powder, mp 324-325°
25D -256° (c = 0.5 in water)
Boiling point:
Flash point:
storage temp. 
H2O: soluble5mg/mL, clear (warmed)
white to beige
Water Solubility 
Sparingly soluble in water. Soluble in DMSO
CAS DataBase Reference
186826-86-8(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
Avelox; moxifloxacin hydrochloride
NCI Drug Dictionary
  • Risk and Safety Statements
WGK Germany  2
HazardClass  IRRITANT

Moxifloxacin hydrochloride price More Price(60)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich PHR1542 Moxifloxacin hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material 186826-86-8 1g $84.2 2021-12-16 Buy
Sigma-Aldrich Y0000703 Moxifloxacin hydrochloride European Pharmacopoeia (EP) Reference Standard 186826-86-8 $190 2021-12-16 Buy
Sigma-Aldrich 1448606 Moxifloxacin hydrochloride United States Pharmacopeia (USP) Reference Standard 186826-86-8 200mg $969 2021-12-16 Buy
Alfa Aesar J66626 Moxifloxacin hydrochloride, 97% 186826-86-8 500mg $528 2021-12-16 Buy
Alfa Aesar J66626 Moxifloxacin hydrochloride, 97% 186826-86-8 100mg $121 2021-12-16 Buy

Moxifloxacin hydrochloride Chemical Properties,Uses,Production

Indications and Usage

Moxifloxacin Hydrochloride is a fluoroquinolone antibiotic developed by Bayer Pharmaceuticals (Germany.) It can be used to treat community-acquired pneumonia caused by Staphylococcus aureus, baccilus, pneumococcus, mucositis Moraxella, and Klebsiella pneumoniae, acute chronic bronchitis attacks, and acute sinusitis. For the treatment of adult bacterial lung infections, paranasal sinus, skin, and abdominal cavity. Also used to treat community-acquired pneumonia, chronic bronchitis, urogenital infection, and acute sinusitis.

Mechanisms of Action

Its active mechanisms and in vitro antibacterial spectrums are similar to those of other fluoroquinolones, but its profile towards gram-positive and anaerobic bacteria is similar to that of trovafloxacin, better than some older drugs. Compared with other fluoroquinolones, few gram-positive bacteria are resistant to Moxifloxacin Hydrochloride, or the spread of resistance is very slow. Gram-negative and enterococci strains with cross resistance to other fluoroquinolones have been found. It is effective at least against Staphylococcus aureus strains grlA, grlB, gyrA and gyrBcan, and 0.5-2 mg/L can inhibit Ciprofloxacin resistant Staphylococcus aureus, from large MIC to small Ciprofloxacin, Ofloxacin, Levofloxacin, Sparfloxacin, and Moxifloxacin.


After 45 healthy volunteers were orally administered single doses of 50-800 mg, their peak plasma concentration and area under the curve (AUC) increased linearly with dosage. Recommended oral dose is 400 mg, average Cmax is 2.5mg/L, peak time (tmax) is 1.5 hours, and AUC is 26.9 mg•h/L. For healthy volunteers who took 400 mg per day orally for 10 days, Cmax was 4.52 mg/L, 1.59 accumulated over 10 days. Oral bioavailability is 89%, apparent distribution volume 3.55 L/kg, plasma protein binding rate 48%. For 400 mg intravenously, Cmaxis 3.62 mg/L. AUC 34.6 mg•h/L. 24 hours after 13 healthy volunteers were given a single oral dose or intravenous injection of 400 mg, skin blister fluid concentration was twice that of serum, suggesting easier penetration of interstitial tissue. One hour after 18 patients ingested a single oral dose of 400 mg before undergoing bronchoscopy, bronchial epithelial cell fluid and bronchial biopsy tissue concentrations were 24.4 and 5.5 mg / L respectively, greater than the plasma concentration after 12 hours. An extremely high concentration (113.6 mg/L) was reached in macrophages. After 34 patients with chronic sinusitis received 5 oral doses of 400 mg, concentration in maxillary sinus mucosa exceeded blood plasma concentration. Three hours after the last dose, blood concentration peaked at 7.47 mg/kg; after 36 hours it was 1.25 mg/kg,suggesting a post-dosage effect.
After healthy volunteers received an oral dose of 400 mg, total clearance rate and renal clearance rates were 14.9 and 3.03 L per hour respectively. The drug apparently does not undergo P450 metabolism. Metabolized in vitro into N-sulfate and acyl glucuronide, metabolites inactive. After healthy volunteers took 400 mg/d orally, the average elimination half-life (t1/2β) during the first day was 9.3 hours, 11.95 hours over 10 days. Another study showed that the average t1/2β is about 10-16 hours. After a single oral dose or intravenous infusion of 400 mg, the urine reabsorption rates were 19%-20% and 22% respectively.

Adverse Effects

The adverse effects of this product are mostly mild and transient, and 3.8% of patients discontinued treatment as a result of adverse effects. The most common effects were nausea (7.2%) and diarrhea (5.7%). The incidence of dizziness was 2.8%. Healthy volunteers experienced no changes in vital signs, hematology, blood biochemistry, and ECG. Studies show that it is different from lomefloxacin and did not show any phototoxicity.

Warnings and Precautions

Similar to other fluoroquinones, bioavailability of 400 mg of Moxifloxacin Hydrochloride declined significantly after combination with antacids. AUC and cmax decreased 45% and 40% compared with when used alone, but Moxifloxacin Hydrochloride absorption was not significantly affected when taken 2 hours before or 4 hours after taking antacids. When taken with iron, absorption decreased significantly, with AUC and cmax was 39% and 59% lower, respectively. No interaction with theophylline, probenecid, ranitidine, or warfarine.

Adverse reactions

Side effects of this product are mostly mild and transient , 3.8% of the patient discontinued treatment due to adverse events . The most common adverse reactions are nausea (7.2%) and diarrhea (5.7%). Dizziness is 2.8%. In healthy volunteers, no changes in vital signs, hematology, blood biochemistry and electrocardiogram.
Studies have shown that the product is different from lomefloxacin , no drug-induced light toxicity.


Similar to other fluoroquinolones , the product (400mg) in combination with antacids, bioavailability will fall significantly, AUC and cmax fall down 45% and 40% respectively when compared with alone, but using the moxifloxacin hydrochloride 2h before taking antacids or using antacids 4h after using this service, the absorption of the drug has no effect. If the product in combination with iron ,absorption rate decreases, AUC and cmax are reduced by 39% and 59%. The product has no interaction with theophylline, probenecid, ranitidine and warfarin .


Moxifloxacin is a fluoroquinolone antibiotic. It is active against 390 clinical isolates of aerobic and anaerobic Gram-positive and Gram-negative bacteria (MIC90s = ≤0.25 μg/ml), as well as clinical isolates of methicillin-susceptible and -resistant S. aureus (MIC90s = 0.12 and 2 μg/ml, respectively). Moxifloxacin is an inhibitor of E. coli DNA gyrase that is selective for DNA gyrase over E. coli topoisomerase IV (IC50s = 0.51 and 38.8 mg/L, respectively, in cell-free assays). It prevents S. aureus- or P. aeruginosa-induced increases in bronchoalveolar lavage fluid (BALF) neutrophil infiltration and reduces S. aureus- or P. aeruginosa-induced increases in lung chemokine (C-X-C motif) ligand 1 (CXCL1) and IL-1β levels in mouse models of bacterial pneumonia when administered at a dose of 100 mg/kg twice per day for two days. Moxifloxacin (100 mg/kg) decreases the number of lung and spleen colony forming units (CFUs) in a mouse model of systemic M. tuberculosis infection. Formulations containing moxifloxacin have been used in the treatment of various bacterial infections.


Moxifioxacin hydrochlodde is one of the two new fluoroquinolonecarboxylic acid antibiotics introduced in 1999 for the treatment of respiratory tract infections such as community-acquired pneumonia, acute exacerbations of bronchitis or acute sinusitis. Moxifloxacin can be synthesized through a 12 step sequence from the classical 4-quinolone-3-carboxylic acid template. Some advantages of Moxifloxacin over Ciprofloxacin, another of Bayer's launched quinolones, have been shown, i.e. an enhanced activity against Gram-positive bacteria (Streptococcus pneumoniae, Clostndium pneumoniae), a favorable pharmacokinetic profile (good tissue penetration and plasma concentrations above MICs) and a lack of phototoxicity (UVA irradiation).

Chemical Properties

Light yellow to yellow crystalline powder


Bayer (Germany)


Moxifloxacin Hydrochloride is an antibacterial agent that inhibits the activities of Topo II (DNA gyrase) and topoisomerase IV.


acetylcholinesterase inhibitor (reversible), cognitive enhancer


An antibacterial agent that inhibits the activities of Topo II (DNA gyrase) and topoisomerase IV


ChEBI: A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.

Manufacturing Process

Manufacturing process for Moxifloxacin hydrochloride includes 3 steps: Synthesis of intermidate octahydropyrrolo[3,4-b]pyridine (2,8- diazabicyclo[4.3.0]nonane);Synthesis of intermidate 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4- oxo-3-quinolinecarboxylic acid;Syntesis of 1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4- dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride (moxifloxacin hydrochloride)

brand name

Avelox (Bayer); Vigamox (Alcon.

Therapeutic Function


Moxifloxacin hydrochloride Preparation Products And Raw materials

Raw materials

Preparation Products

Moxifloxacin hydrochloride Suppliers

Global( 490)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Jinan Ande Pharmaceutical Co.,Ltd.
+8613256107535 CHINA 220 58
Capot Chemical Co.,Ltd.
+86(0)13336195806 +86-571-85586718
+86-571-85864795 China 20012 60
Henan DaKen Chemical CO.,LTD.
+86-371-66670886 China 15418 58
Nanjing Gold Pharmaceutical Technology Co. Ltd.
025-84209270 15906146951
025-84209270 CHINA 115 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 China 22607 55
Hangzhou FandaChem Co.,Ltd.
+86-571-56059825 China 9165 55
Guangzhou PI PI Biotech Inc
020-81716319; China 3284 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 26781 60
Hefei TNJ Chemical Industry Co.,Ltd.
86-0551-65418697 China 3000 55
career henan chemical co
+86-0371-55982848 China 29953 58

View Lastest Price from Moxifloxacin hydrochloride manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2022-01-26 Moxifloxacin Hcl
US $0.00 / KG 1KG 99% 100 Jinan Ande Pharmaceutical Co.,Ltd.
2022-01-25 Moxifloxacin hydrochloride
2021-12-01 Moxifloxacin HCl
US $10.50 / KG 1KG 99% 10 ton Hebei Crovell Biotech Co Ltd

186826-86-8(Moxifloxacin hydrochloride)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved